title: [Cutaneous calciphylaxis].
abstract: Calciphylaxis represents a dermatological emergency with a mortality of up to 80%. The disease is characterized by a triad of arteriolar medial calcification, thrombotic cutaneous ischemia and necrotic ulcerations. Recently several mechanisms of vascular calcification have been identified. This may led to preventive measures in the future. Early diagnosis is important to avoid complications such as sepsis. The dermatologist plays an important role in early diagnosis based on the recognition of clinical presentation and histopathology. Patients with end-stage renal disease are most commonly affected by calciphylaxis. The most frequent non-uremic predisposing conditions are primary hyperparathyroidism, malignancies, alcohol-induced liver disease, and autoimmune connective tissue diseases. Medical treatment aims to normalize mineral metabolism to reduce the serum concentration of sodium phosphate and thus to prevent precipitation and calcification. Newer compounds are bisphosphonates, non-sodium/non-aluminium phosphate binders, cinacalcet, paricalcitrol, and sodium thiosulfate. Among the surgical procedures parathyroidectomy did not result in a significant survival benefit. An aggressive surgical debridement of necrotic ulcerations, on the other hand, improved survival. Early diagnosis and a multidisciplinary treatment approach including re-vascularization by the vascular surgeon, repeated surgical debridement and split skin transplantation support wound healing and insure limb conservation.
authors.affiliation: Klinik für Dermatologie und Allergologie, Krankenhaus Dresden-Friedrichstadt, Städtisches Klinikum, Akademisches Lehrkrankenhaus der Technischen Universität Dresden, Friedrichstr. 41, 01067, Dresden. wollina-uw@khdf.de
authors.forename: U
authors.initials: U
authors.lastname: Wollina
mesh_terms: D001706:Biopsy; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D002115:Calciphylaxis / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D002614:Chelating Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003646:Debridement; D003937:Diagnosis, Differential; D004164:Diphosphonates / Q000627:therapeutic use; D004872:Ergocalciferols / Q000627:therapeutic use; D006801:Humans; D006961:Hyperparathyroidism / Q000150:complications; D007676:Kidney Failure, Chronic / Q000150:complications; D009336:Necrosis; D054843:Negative-Pressure Wound Therapy; D011379:Prognosis; D012307:Risk Factors; D012867:Skin / Q000473:pathology; D012875:Skin Diseases, Metabolic / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D013885:Thiosulfates / Q000627:therapeutic use
chemical_list: D050071:Bone Density Conservation Agents; D002614:Chelating Agents; D004164:Diphosphonates; D004872:Ergocalciferols; D013885:Thiosulfates; C084656:paricalcitol; C017717:sodium thiosulfate